PPARγ activation following apoptotic cell instillation promotes resolution of lung inflammation and fibrosis via regulation of efferocytosis and proresolving cytokines

Mucosal Immunology

Volumn 8, Issue 5, 2015, Pages 1031-1046

  Yoon, Y S ^a   Kim, S Y ^a   Kim, M J ^a   Lim, J H ^a   Cho, M S ^a   Kang, J L ^a  

^a Ewha Womans University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; ALPHA SMOOTH MUSCLE ACTIN; ARGINASE 1; BLEOMYCIN; CASPASE 3; CASPASE 9; CD36 ANTIGEN; COLLAGEN; COLLAGEN TYPE 1 ALPHA2; FIBRONECTIN; HYDROXYPROLINE; INTERLEUKIN 10; MACROPHAGE MANNOSE RECEPTOR; MANNOSE RECEPTOR; MESSENGER RNA; MYELOPEROXIDASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SCATTER FACTOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; 2-CHLORO-5-NITROBENZANILIDE; ANILIDE; CYTOKINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; C57BL 6 MOUSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EFFEROCYTOSIS; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LUNG; LUNG ALVEOLUS MACROPHAGE; LUNG FIBROSIS; MALE; MOUSE; NEUTROPHIL; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; SURVIVAL RATE; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DRUG EFFECTS; HELA CELL LINE; IMMUNOLOGY; JURKAT CELL LINE; PATHOLOGY;

ANILIDES; ANIMALS; APOPTOSIS; BLEOMYCIN; CYTOKINES; HELA CELLS; HUMANS; JURKAT CELLS; LUNG; MALE; MICE; PNEUMONIA; PPAR GAMMA; PULMONARY FIBROSIS;

EID: 84937686737     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2014.130     Document Type: Article

References (64)

1. Thannickal, V.J., Toews, G.B., White, E.S., Lynch, J.P. III & Martinez, F.J. Mechanisms of pulmonary fibrosis. Annu. Rev. Med. 5, 395-417 (2004).
2. Harari, S. & Caminati, A. IPF: new insight on pathogenesis and treatment. Allergy 5, 537-553 (2010).
3. Vandivier, R.W., Henson, P.M. & Douglas, I.S. Burying the dead. The impact of failed apoptotic cell removal (efferocytosis) on chronic inflammatory lung disease. Chest 129, 1673-1682 (2006).
4. Voll, R. E., Herrmann,M., Roth, E. A., Stach, C., Kalden, J. R & Girkontaite, I. Immunosuppressive effects of apoptotic cells. Nature 390, 350-351 (1997).
5. Fadok, V. A., Voelker, D. R., Campbell, P. A., Cohen, J. J., Bratton, D. L. & Henson, P. M. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J. Immunol. 148, 2207-2216 (1992).
6. Majai, G., Sarang, Z., Csomós, K., Zahuczky,G. & Fésu7die;s, L. PPARgammadependent regulation of human macrophages in phagocytosis of apoptotic cells. Eur. J. Immunol. 37, 1343-1354 (2007).
7. Asada, K., Sasaki, S., Suda, T., Chida, K. & Nakamura, H. Antiinflammatory roles of peroxisome proliferator-activated receptor gamma in human alveolar macrophages. Am. J. Respir. Crit. Care Med. 169, 195-200 (2004).
8. Odegaard, J.I. et al. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 447, 1116-1120 (2007).
9. Fernandez-Boyanapalli, R.F. et al. Impaired apoptotic cell clearance in CGD due to altered macrophage programming is reversed by phosphatidylserine-dependent production of IL-4. Blood 113, 2047-2055 (2009).
10. Nolan, J.J., Ludvik, B., Beerdsen, P., Joyce, M. & Olefsky, J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N. Engl. J. Med. 331, 1188-1193 (1994).
11. Tontonoz, P. et al. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc.Natl. Acad. Sci. USA 94, 237-241 (1997).
12. Chang, T.H. & Szabo, E. Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer. Cancer Res. 60, 1129-1138 (2000).
13. Ricote, M., Li, A.C.,Willson, T.M., Kelly, C.J. & Glass, C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391, 79-82 (1998).
14. Simon, D.M. et al. Epithelial cell PPARg is an endogenous regulator of normal lung maturation and maintenance. Proc. Am. Thorac. Soc. 3, 510-511 (2006).
15. Uto, H. et al. The peroxisome proliferator-activated receptor-g agonist, pioglitazone, inhibits fat accumulation and fibrosis in the livers of rats fed a choline-deficient, L-amino acid-defined diet. Hepatol. Res. 32, 235-242 (2005).
16. Calkin, A.C., Giunti, S., Jandeleit-Dahm, K.A., Allen, T.J., Cooper, M.E. & Thomas, M.C. PPAR-a and-g agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse. Nephrol. Dial. Transplant. 21, 2399-2405 (2006).
17. Zhao, C., Chen, W., Yang, L., Chen, L., Stimpson, S.A. & Diehl, A.M. PPARg agonists prevent TGFb1/Smad3-signaling in human hepatic stellate cells. Biochem. Biophys. Res. Commun. 350, 385-391 (2006).
18. Milam, J.E. et al. PPAR-gamma agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis. Am. J. Physiol. Lung Cell Mol. Physiol 294, L891-L901 (2008).
19. Genovese, T. et al. Effect of rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2 on bleomycin-induced lung injury. Eur. Respir. J. 25, 225-234 (2005).
20. Li, Y., Wen, X., Spataro, B.C., Hu, K., Dai, C. & Liu, Y. Hepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferator-activated receptor-g agonists. J. Am. Soc. Nephrol. 17, 54-65 (2006).
21. Shimabukuro, D.W., Sawa, T. & Gropper, M.A. Injury and repair in lung and airways. Crit. Care Med. 31, S524-S531 (2003).
22. Peng, R. et al. Bleomycin induces molecular changes directly relevant to idiopathic pulmonary fibrosis: a model for 'active' disease. PLoS One 8, e59348 (2013).
23. Chung, M.P., Monick, M.M., Hamzeh, N.Y., Butler, N.S., Powers, L.S. & Hunninghake, G.W. Role of repeated lung injury and genetic background in bleomycin-induced fibrosis. Am. J. Respir.CellMol. Biol. 29, 375-380 (2003).
24. Lee, Y.J. et al. Apoptotic cell instillation after bleomycin attenuates lung injury through hepatocyte growth factor induction. Eur. Respir. J. 40, 424-435 (2012).
25. Huynh, M.L., Fadok, V.A. & Henson, P.M. Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation. J. Clin. Invest. 109, 41-50 (2002).
26. Freire-de-Lima, C.G., Xiao, Y.Q., Gardai, S.J., Bratton, D.L., Schiemann, W.P. & Henson, PM Apoptotic cells, through transforming growth factorbeta, coordinately induce anti-inflammatory and suppress pro-inflammatory eicosanoid and NO synthesis in murine macrophages. J. Biol. Chem. 281, 38376-38384 (2006).
27. Coste, A. et al. PPARgamma promotes mannose receptor gene expression in murine macrophages and contributes to the induction of this receptor by IL-13. Immunity 19, 329-339 (2003).
28. Kiss, R.S., Elliott, M.R., Ma, Z., Marcel, Y.L. & Ravichandran, K.S. Apoptotic cells induce a phosphatidylserine-dependent homeostatic response from phagocytes. Curr. Biol. 16, 2252-2258 (2006).
29. Frasch, S.C. et al. Signaling via macrophage G2A enhances efferocytosis of dying neutrophils by augmentation of Rac activity. J. Biol. Chem. 286, 12108-12122 (2011).
30. Ricote, M. & Glass, C.K. PPARs and molecular mechanisms of transrepression. Biochim. Biophys. Acta 1771, 926-935 (2007).
31. Yoon, Y.S., Lee, Y.J., Choi, J.Y., Cho, M.S. & Kang, J.L. Coordinated induction of cyclooxygenase-2/prostaglandin E2 and hepatocyte growth factor by apoptotic cells prevents lung fibrosis. J. Leukoc. Biol. 94, 1037-1049 (2013).
32. Jiang, J.G., Johnson, C. & Zarnegar, R. PPAR gamma-mediated transcriptional upregulation of the hepatocyte growth factor gene promoter via a novel composite cis-acting element. J. Biol. Chem. 276, 25049-25056 (2001).
33. Kikuchi, N. et al. Nrf2 protects against pulmonary fibrosis by regulating the lung oxidant level and Th1/Th2 balance. Respir. Res. 11, 31-42 (2010).
34. Segel, M.J. et al. Role of interferon-gamma in the evolution of murine bleomycin lung fibrosis. Am. J. Physiol. Lung Cell Mol. Physiol 285, L1255-L1262 (2003).
35. Ziesche, R., Hofbauer, E., Wittmann, K., Petkov, V. & Block, L.H. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 341, 1264-1269 (1999).
36. Izumo, T., Kondo, M. & Nagai, A. Effects of a leukotriene B4 receptor antagonist on bleomycin-induced pulmonary fibrosis. Eur. Respir. J. 34, 1444-1451 (2009).
37. Ren, Y. et al. Apoptotic cells protect mice against lipopolysaccharideinduced shock. J. Immunol. 180, 4978-4985 (2008).
38. Kleinclauss, F. et al. Intravenous apoptotic spleen cell infusion induces a TGF-b-dependent regulatory T-cell expansion. Cell Death Differ. 13, 41-52 (2006).
39. Perruche, S., Saas, P. & Chen,W. Apoptotic cell-mediated suppression of streptococcal cell wall-induced arthritis is associated with alteration of macrophage function and local regulatory T-cell increase: a potential cell-based therapy? Arthritis Res. Ther. 11, R104-R111 (2009).
40. Xia, C.Q.,Peng,R., Qiu, Y., Annamalai, M.,Gordon,D. & Clare-Salzler, M.J. Transfusion of apoptotic beta-cells induces immune tolerance to beta-cell antigens and prevents type 1 diabetes in NOD mice. Diabetes 56, 2116-2123 (2007).
41. Wynn, T.A. & Barron, L. Macrophages: master regulators of inflammation and fibrosis. Semin. Liver Dis. 30, 245-257 (2010).
42. Gordon, S. Alternative activation of macrophages. Nat. Rev. Immunol. 3, 23-35 (2003).
43. Gibbons, M.A. et al. Ly6Chi monocytes direct alternatively activated profibrotic macrophage regulation of lung fibrosis. Am. J. Respir. Crit. Care Med. 184, 569-581 (2011).
44. Pociask, D.A., Chen, K., Choi, S.M., Oury, T.D., Steele, C. & Kolls, J.K. gd T cells attenuate bleomycin-induced fibrosis through the production of CXCL10. Am. J. Pathol. 178, 1167-1176 (2011).
45. Cao, H. et al. Hydrogen sulfide protects against bleomycin-induced pulmonary fibrosis in rats by inhibiting NF-kB expression and regulating Th1/Th2 balance. Toxicol. Lett. 224, 387-394 (2014).
46. Cooper, J.A.D. Pulmonary fibrosis pathways are slowly coming into light. Am. J. Respir. Cell Mol. Biol. 22, 520-523 (2000).
47. Standiford, T.J., Keshamouni, V.G. & Reddy, R.C. Peroxisome proliferatoractivated receptor-{gamma} as a regulator of lung inflammation and repair. Proc. Am. Thorac. Soc. 2, 226-231 (2005).
48. Morimoto, K., Janssen, W.J. & Terada, M. Defective efferocytosis by alveolar macrophages in IPF patients. Respir. Med. 106, 1800-1803 (2012).
49. Poon, I.K., Lucas, C.D., Rossi, A.G. & Ravichandran, K.S. Apoptotic cell clearance: basic biology and therapeutic potential. Nat. Rev. Immunol. 14, 166-180 (2014).
50. Mukundan, L. et al. PPAR-delta senses and orchestrates clearance of apoptotic cells to promote tolerance. Nat. Med. 15, 1266-1272 (2009).
51. Roszer, T. et al. Autoimmune kidney disease and impaired engulfment of apoptotic cells in mice with macrophage peroxisome proliferator-activated receptor gamma or retinoid X receptor alpha deficiency. J. Immunol. 186, 621-631 (2011).
52. Brown, J.R., Goldblatt, D., Buddle, J., Morton, L. & Thrasher, A.J. Diminished production of anti-inflammatory mediators during neutrophil apoptosis and macrophage phagocytosis in chronic granulomatous disease (CGD). J. Leukoc. Biol. 73, 591-599 (2003).
53. White, E.S., Lazar, M.H. & Thannickal, V.J. Pathogenetic mechanisms in usual interstitial pneumonia/idiopathic pulmonary fibrosis. J. Pathol. 201, 343-354 (2003).
54. Tan, X., Dagher, H., Hutton, C.A. & Bourke, J.E. Effects of PPAR gamma ligands on TGF-beta1-induced epithelial-mesenchymal transition in alveolar epithelial cells. Respir. Res. 11, 21-33 (2010).
55. Burgess, H.A. et al. PPARgamma agonists inhibit TGF-beta induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis. Am. J. Physiol. LungCell Mol. Physiol. 288, L1146-L1153 (2005).
56. Ghosh, A.K., Bhattacharyya, S., Lakos, G., Chen, S.J., Mori, Y. & Varga, J. Disruption of transforming growth factor beta signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma. Arthritis Rheum. 50, 1305-1318 (2004).
57. Fan, S. et al. The cytokine hepatocyte growth factor/scatter factor inhibits apoptosis and enhances DNA repair by a common mechanism involving signaling through phosphatidyl inositol 30 kinase. Oncogene 19, 2212-2223 (2000).
58. Zhang, A., Wang, M.H., Dong, Z. & Yang, T. Prostaglandin E2 is a potent inhibitor of epithelial-to-mesenchymal transition: interaction with hepatocyte growth factor. Am. J. Physiol. Renal Physiol. 291, F1323-F1331 (2006).
59. Shukla, M.N., Rose, J.L., Ray, R., Lathrop, K.L., Ray, A. & Ray, P. Hepatocyte growth factor inhibits epithelial to myofibroblast transition in lung cells via SMAD7. Am. J. Respir. Cell Mol. Biol. 40, 643-653 (2009).
60. Nakagome, K., Dohi, M., Okunishi, K., Tanaka, R., Miyazaki, J. & Yamamoto, K. In vivo IL-10 gene delivery attenuates bleomycin induced pulmonary fibrosis by inhibiting the production and activation of TGF-beta in the lung. Thorax 61, 886-894 (2006).
61. Polvani, S., Tarocchi, M. & Galli, A. PPARg and oxidative stress: Con(b) catenating NRF2 and FOXO. PPAR Res. 2012, 641087 (2012).
62. Rao, G.V.S. et al. Efficacy of a technique for exposing the mouse lung to particles aspirated from the pharynx. J. Toxicol. Environ. Health A 66, 1441-1452 (2003).
63. Collin, M., Patel, N.S., Dugo, L. & Thiemermann, C. Role of peroxisome proliferator-activated receptor-gamma in the protection afforded by 15-deoxydelta12,14 prostaglandin J2 against the multiple organ failure caused by endotoxin. Crit. Care Med. 32, 826-831 (2004).
64. Hoffman,P.R. et al. Phosphatidylserine (PS) induces PSreceptor-mediated macropinocytosis and promotes clearance of apoptotic cells. J. Cell Biol. 155, 649-659 (2001).